Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
NuCana plc (NCNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 6-K Quarterly results
08/16/2023 6-K Quarterly results
Docs: "6-K",
"Unaudited Condensed Consolidated Financial Statements as of June 30, 2023 and for the Three and Six Months Ended June 30, 2023 and 2022",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Six Months Ended June 30, 2023 and 2022",
"NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update"
06/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
05/17/2023 6-K Quarterly results
Docs: "6-K",
"Unaudited Condensed Consolidated Financial Statements as of March 31, 2023 and for the Three Months Ended March 31, 2023 and 2022",
"Management's Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2023 and 2022",
"NuCana Reports First Quarter 2023 Financial Results and Provides Business Update"
05/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NuCana Announces Receipt of Nasdaq Notice Edinburgh, United Kingdom, May 12, 2023 - NuCana plc announced that it received written notification from The Nasdaq Stock Market LLC dated May 9, 2023, indicating that, based upon a closing bid price of less than $1.00 per share for the Company's American Depositary Shares for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450. The Notification Letter has no immediate effect on the listing of the ADSs, and they will continue to trade on The Nasdaq Global Select Market under the symbol “NCNA”. Pursuant to Nasdaq Listing Rule 5810, the applicable grace period to regain compliance is 180 days, or until November 6, 2023. The Company intends to monitor the closing bid price of its ADSs during this gra..."
04/14/2023 6-K Quarterly results
04/04/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/04/2023 6-K Quarterly results
Docs: "6-K",
"NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update"
03/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/23/2023 SC 13G/A BAILLIE GIFFORD & CO reports a 7% stake in NUCANA PLC
01/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement Edinburgh, United Kingdom, January 23, 2023 - NuCana plc , , announced that it has received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market, LLC informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450 and the matter is closed. As announced on January 6, 2023, the Company was notified by Nasdaq that it was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the Company's American Depositary Shares had been below $1.00 for 30 consecutive business days. To regain compliance with the Minimum Bid Price Requirement, NuCana was required to maintain a minimu..."
01/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NuCana Announces Receipt of NASDAQ Notice Edinburgh, United Kingdom, January 6, 2023 - NuCana plc announced that it received written notification from The Nasdaq Stock Market LLC dated January 3, 2023, indicating that, based upon a closing bid price of less than $1.00 per share for the Company's American Depositary Shares for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450. The Notification Letter has no immediate effect on the listing of the ADSs, and they will continue to trade on The Nasdaq Global Select Market under the symbol “NCNA”. Pursuant to Nasdaq Listing Rule 5810, the applicable grace period to regain compliance is 180 days, or until July 3, 2023. The Company intends to monitor the closing bid price of its ADSs during this ..."
11/16/2022 6-K Quarterly results
Docs: "6-K",
"Unaudited Condensed Consolidated Financial Statements as of September 30, 2022 and for the Three and Nine Months Ended September 30, 2022 and 2021",
"Management's Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months Ended September 30, 2022 and 2021",
"NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update"
10/26/2022 6-K Quarterly results
09/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology Annual Meeting 2022"
09/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology Annual Meeting 2022"
09/06/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NuCana Announces Presentations at the European Society for Medical Oncology Congress 2022 Edinburgh, United Kingdom, September 6, 2022 —NuCana plc announced two presentations at the European Society for Medical Oncology Congress 2022 being held September 9-13, 2022 at the Paris Expo Porte de Versailles in Paris, France. The details of NuCana's presentations at ESMO are as follows: Title: NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin or irinotecan in patients with advanced colorectal cancer Abstract Number: 1752 Presentation: 345P Presentation Date & Time: Sunday, September 11, 2022 at 9:00 a.m. CEST Location: Hall 4 and the virtual Congress platform Presenting Author: Andrew L. Coveler Title: NUC-7738 in patients with advanced solid tumours: Phase I results f..."
08/17/2022 6-K Quarterly results
08/11/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement Edinburgh, United Kingdom, July 27, 2022 - NuCana plc , , announced that it has received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market, LLC informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450 and the matter is closed. As announced on June 3, 2022, the Company was notified by Nasdaq that it was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the Company's American Depositary Shares had been below $1.00 for 30 consecutive business days. To regain compliance with the Minimum Bid Price Requirement, NuCana was required to maintain a minimum clos..."
07/11/2022 6-K Quarterly results
06/23/2022 6-K Quarterly results
06/10/2022 6-K Quarterly results
06/03/2022 6-K Quarterly results
06/02/2022 6-K Quarterly results
05/23/2022 6-K Quarterly results
04/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update"
03/08/2022 6-K Quarterly results
03/02/2022 6-K Quarterly results
02/25/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/22/2022 6-K Quarterly results
02/11/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy